INTRODUCTION
It is well known that the human immunodeficiency virus (HIV) is the causative agent for acquired immunodeficiency syndrome (AIDS). [1] In the last few decades, advances in antiretroviral therapies have led to various approved protease inhibitors (PIs) for the treatment of HIV/AIDS. Several PIs have been used successfully in combination therapy with reverse transcriptase inhibitors and other antiviral drugs, and are among the top 200 drugs sold in the United States. As a consequence, HIV/AIDS can now be perceived as a manageable chronic infection. Despite major advances in antiretroviral therapies, current drugs have several drawbacks, such as i) high daily pill burden, ii) poor metabolic profiles, iii) decrease in efficacy through drug interactions, and iv) a high resistance barrier. [2] The emergence of drug resistance has become a serious problem leading to ineffective therapies. [3] Because of continuing resistance, there is a pressing need for new PIs with improved properties and activities. [4] HIV protease cleaves viral proteins in order to generate mature infectious virions. [5] It is composed of two subunits where the catalytic active site of the enzyme is the dimer interface comprised of two aspartic acid residues (Asp25 and Asp25'). Also, the enzyme's active site possesses distinct subsites S1, S1', S2, S2', S3 and S3'. Different subsites can accommodate hydrophobic or polar side chains. [6] When the PI binds to the active site, it prevents cleavage of nascent viral proteins, thereby halting viral replication. [7] First-generation PIs were approved by the Food and Drugs Administration (FDA) in the mid-90's. Also, this era marked the beginning of combination therapy for the treatment of HIV/AIDS. Careful inspection of the first generation inhibitors 1-5 reveals hydroxyethylene and hydroxyethylamine central cores ( Figure 1a) . The rapid emergence of resistance led to the development of second-generation PIs ( Figure   1b ). Inhibitors 6-8 were developed not only to overcome drug resistance but also to resolve other challenging issues such as high metabolic clearance, low half-life and poor oral bioavailability. The pharmaceutical industry reduced substantially their investment in the development of PIs, because new therapies must demonstrate superiority over existing treatment. Nevertheless, recent progress in the development of new classes of inhibitors [8] has led to candidates showing clinical promise. [9] Some diolbased inhibitors have also emerged in recent years ( Figure 1c) . The diol moiety of inhibitors 9-11 [10] is believed to interact with the two aspartate residues of the binding site. Nonetheless, the development of new PIs is still ongoing [11] and finding novel PIs with broad-spectrum activities against multidrugresistant variants is most certainly the biggest challenge to overcome.
[12] Typically, D-Mannitol [13] and L-mannonic-g-lactone [10c, 14] have been used as starting points for the preparation of PIs. However, this approach generally leads to C2-symmetrical compounds. Since nonsymmetrical inhibitors have superior activities, [15] new routes from simple chiral building blocks are clearly needed. To date, there is only one report describing the use of methyl b-D-mannopyranoside for the synthesis of PIs. [16] Similarly, peptidic diolbased PIs have been successfully designed for the purpose of probing favorable interactions with the HIV protease backbone. [10b, 17] Besides HIV/AIDS, there has been growing interest in repurposing PIs for the treatment of cancer. [18] Although the mechanism of antitumor action of such drugs is under debate, [19] early clinical trials employing a PI alone or in combination with radiotherapy [20] have shown promise in treating patients with various types of cancer, including adenocarcinoma and non-small cell lung cancer (NSCLC). [21] Herein, we describe the synthesis of novel nonsymmetrical diol-based peptidomimetics of general structure 12 (Scheme 1), which incorporate prominent structural features of the HIV protease inhibitors shown in Figure 1 . From a retrosynthetic perspective, azides 13 were viewed as key intermediates, accessible through aminolysis of lactones 14 (Scheme 1). The desired benzyl substituent in 14 would be installed in stereodivergent fashion by conjugate addition onto ,-unsaturated lactone 15, derived from inexpensive D-glucal 16. Our approach offers considerable flexibility as it enables parallel assemblage of small molecule libraries with distinct molecular architectures from chiral and achiral fragments.
Scheme 1. Retrosynthetic analysis of nonsymmetrical diol 12
RESULTS AND DISCUSSION
The synthesis began from D-glucal 16 following a known 3-step sequence (Scheme 2).
[22] Selective tosylation of the primary alcohol in 16, followed by acetylation of the sec-hydroxyl groups provided intermediate 17 in 70% yield over 2 steps. Next, nucleophilic displacement of the tosylate with azide yielded glycal 18 in high yield. Treatment of 18 with boron trifluoride and 3-chloroperbenzoic acid (m-CPBA) at -20 °C for 0.5 h led directly to ,-unsaturated g-lactone 19. [23] Attempts to hydrolyze the acetyl ester group in 19 under standard basic conditions resulted in complete decomposition. Ultimately, the desired hydrolysis to alcohol 20 was successfully accomplished using Amano Lipase PS from Burkholderia cepacia. [24] Exposure of 20 to benzyl bromide and silver oxide afforded the rather unstable ether 15 in 59% yield over 2 steps. [25] Conjugate addition of in situ generated benzyl cuprate onto 15 proceeded with modest diastereoselectivity to afford lactone 14 as an inseparable ~2:1 mixture of isomers, whose respective identities were deduced after ring opening (vide infra). [26] The major isomer of 14 (not shown) arose by addition trans to the adjacent benyloxy substituent.
Scheme 2. Synthesis of intermediate 14
At this point the isomer mixture 14 was subjected to heating with amines 21-23 in MeOH to generate gluconamide derivatives 24-26 (Scheme 3). [27] The three amines used, namely, butylamine 21, (S)-tetrahydrofuran-3-amine 22 and (1S,2R)-cis-1-amino-2-indanol 23, were selected for the purpose of exploring interactions of amides 24-26 with the enzyme backbone, targeting hydrophobic S2/S2' pockets. Importantly, separation of the resulting diastereomeric mixtures of amides (24-26) could be readily achieved by flash column chromatography, allowing both the 3,4-syn (24a-26a, major) and 3,4-anti isomers (24b-26b, minor) to be obtained in pure form.
Scheme 3. Aminolysis of lactone 14
With the individual diastereoisomers of 24-26 in hand, their transformation to sulfonamides was addressed ( Table 1) . First, TiCl4 mediated cleavage of the O-benzyl group [28] provided the corresponding diols 27-29 in 81-89% yield. Compounds 27-29 were subjected to a hydrogen atmosphere with a catalytic amount of palladium allowing formation of the amine intermediates. The latter were transformed in situ to sulfonamides 30-32 upon treatment with p-toluenesulfonyl chloride and triethylamine. [29] It is important to note that a sulfonamide residue is encountered in several known PIs. [8] The final step of the synthesis of diol-based peptidomimetics is shown in Table 2 . Alkylation of sulfonamides 30-32 was carried out using isobutyl bromide under basic conditions at 70 °C. Products 33-35 were isolated in yields ranging between 89−96%. Installation of a small alkyl group, such as isobutyl, could improve interactions with the protease backbone. In fact, the structures of our target compounds specifically incorporate features found in darunavir 6 ( Figure 1 ). The stereochemistries of our peptidomimetics were determined by NMR, based on the crystal structure of diol 33b (Figure 2) . [30] This compound was prepared from minor isomer 24b. 
ANTIPROLIFERATIVE ACTIVITY
Compounds 29a, 33a, 34ab, and 35ab were evaluated for their antiproliferative activity on human HT-29 colon adenocarcinoma, M21 skin melanoma, and MCF7 breast carcinoma cell lines according to the NCI/NIH Developmental Therapeutics Program. [31] These particular cell lines were chosen to reflect the types of cancer found in preclinical [32] and clinical trials [33] with existing HIV PIs. The results are summarized in The maximum concentration assessed was 50 M for 35a.
CONCLUSION
We have described the synthesis of a series of novel, non-symmetrical diol-based peptidomimetics using a carbohydrate approach. The synthetic route utilizes conjugate addition as a key step, enabling access to 6.1. General procedure I  lactone opening with various amines
To a solution of lactone 14 (1.0 equiv) in dry MeOH was added amine 2123 (2.0 equiv). The mixture was stirred under refluxed for 16 h. After this time, the mixture was concentrated under reduced pressure and purified by flash column chromatography (hexanes / EtOAc) affording products 2426.
General procedure II  benzyl ether deprotection
To a solution of benzyl ether 2426 (1.0 equiv) in CH2Cl2 at 0 °C was added TiCl4 (1.0 M in CH2Cl2, 5.0 equiv) and the mixture was stirred at 0 °C for 3 h. The mixture was poured in cold water and extracted with ethyl acetate (3 × 10 mL). The combined organic phase were dried over MgSO4, filtered and concentrated under reduced pressure. Flash chromatography (hexanes / EtOAc) afforded products 2729.
General procedure III  azide functionalization
To a solution of azide 2729 (1.0 equiv) in MeOH was added Pd/C (10 mol%). The mixture was stirred under a balloon pressure of hydrogen for 8 h. After this time, the mixture was filtered through a pad of celite and concentrated under reduced pressure. The amine thus generated was used for the next step without further purification. To a solution of the resulting amine in CH2Cl2 at 0 °C was added Et3N (1.5 equiv) and p-toluenesulfonyl chloride (1.2 equiv). The mixture was stirred at room temperature for 16 h, then concentrated under reduced pressure and purified by flash column chromatography (hexanes / EtOAc) affording products 3032.
General procedure IV  sulfonamide alkylation
To a solution of the sulfonamide 3032 (1.0 equiv) in acetonitrile was added K2CO3 (2.0 equiv) and isobutyl bromide (2.0 equiv). The mixture was heated at 65 °C for 16 h. After this time, the mixture was filtered through celite and concentrated under reduced pressure. The crude product was purified by flash column chromatography (hexanes / EtOAc) yielding products 3335.
To a solution of D-glucal 16 (1.6 g, 11.0 mmol) in anhydrous pyridine (30 mL) at 0 °C was added ptoluenesulfonyl chloride (2.3 g, 12.0 mmol, 1.1 equiv). The mixture was stirred vigorously at rt for 3 h, then acetic anhydride (4.1 mL, 43.8 mmol, 4.0 equiv) was added and the mixture was stirred at rt for 16 h. After this time, the mixture was concentrated under reduced pressure, then diluted with CH2Cl2 (100 mL). The organic solution was washed with sat aq CuSO4 (3 × 30 mL), water (5 × 30 mL), and brine (1 × 30 mL). The organic solution was dried over MgSO4, filtered and concentrated under reduced pressure. The product was purified by flash column chromatography on silica gel (hexanes / EtOAc, 7 :
3) to give the title compound 17 (3.2 g, 70%) as colorless oil. The physical and spectroscopic properties for compound 17 match those reported in the literature [34] : IR (NaCl film)  To a solution of 80% anhydrous MCPBA (3.8 g, 17.5 mmol, 1.2 equiv) in dry CH2Cl2 (50 mL) at 20
°C was added a cooled solution (20 °C) of compound 18 (3.7 g, 14.6 mmol, 1.0 equiv) in CH2Cl2 (50 mL). Then, BF3 . OEt2 (0.9 mL, 7.29 mmol, 0.5 equiv) was added dropwise at 20 °C and the mixture was stirred for 15 min. After this time, the solution was poured into a sat aq NaHCO3 solution (50 ml)
containing 10-20 mg of Na2S2O3 (prior warming to rt). The mixture was extracted with CH2Cl2 (3 × 50 ml) and the combined organic solutions were concentrated under reduced pressure. and phosphate buffer pH 7 (20 mL) was added amano lipase PS (from Burkholderia cepacia) (916 mg).
The mixture was stirred at rt for 16 h. After this time, water (50 mL) was added and the mixture was extracted with ethyl acetate (2 × 80 ml). The combined organic solutions were washed with a sat aq NaHCO3 solution (100 ml) and brine (100 ml), dried over MgSO4, filtered and concentrated under 
(3R, 4S, 5R)-6-azido-3-benzyl-4-(benzyloxy)-5-hydroxy-N-((S)-tetrahydrofuran-3-yl)hexanamide (25a) and (3S, 4S, 5R)-6-azido-3-benzyl-4-(benzyloxy)-5-hydroxy-N-((S)-tetrahydrofuran-3-yl)hexanamide (25b)
Following 
Molecular docking
Compounds 33-35 were built in PyMOL Molecular Graphics System (Version 1.8.5.0 Schrödinger, LLC) based on the Darunavir structure, and energy minimized using ConfBuster. [36] Docking simulations were performed using Autodock VINA 1.1.2. [37] The crystal structure coordinates of the wild-type HIV protease in complex with Darunavir were taken from PDB 4LL3. [38] Hydrogen atoms were added using PyMOL for Darunavir and the reduce software version 3.23 for the protease. [39] One crystallographic water molecule, located in the binding pocket and hydrogen-bonded to the amine of ILE50 of both subunits, was kept for the dockings. Docking simulations were carried out using a rigid receptor for the protein with flexibility for the ASP30 and ILE84 side chains, a search space centered on they were grown at 37 °C in a moisturesaturated atmosphere containing 5% CO2.
Antiproliferative activity assay
The growth inhibition potency of all compounds was assessed using the procedure recommended by the National Cancer Institute (NCI) Developmental Therapeutics Program for its drug screening program with slight modifications. [31] Briefly, 96-well Costar microtiter clear plates were seeded with 75 μL of a suspension of either HT-29 (5 x 10 3 ), M21 (3 x 10 3 ), or MCF7 (3.5 x 10 3 ) cells per well in medium.
Plates were incubated for 24 h. Freshly solubilised drugs in DMSO (40 mM) were diluted in fresh medium and 75 μL aliquots containing serially diluted concentrations of the drug were added. Final drug concentrations ranged from 100 μM to 78 nM. DMSO concentration was kept constant at < 0.5% (v/v) to prevent any related toxicity. Plates were incubated for 48 h, after which growth was stopped by the addition of cold trichloroacetic acid to the wells (10% w/v, final concentration). Afterward, plates were incubated at 4 °C for 1 h. Then, plates were washed 5-times with distilled water and a sulforhodamine B solution (0.1% w/v) in 1% acetic acid was added to each well. After 15 min at room temperature, the exceeding dye was removed and was washed 5-times with a solution of 1% acetic acid. Bound dye was
